Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
Adverse effects were minimally reported .
There is little evidence of serious short-term adverse effects in these trials , but they are underpowered to detect rare adverse effects .
REVIEW ER 'S CONCLUSIONS Recombinant human growth hormone ( hGH ) doses between 0.3 - 0.375 mg/kg/wk increase short-term growth in girls with Turner Syndrome ( TS ) by approximately 3 cm in the first year of treatment and by approximately 2 cm per year after 2 years of treatment .
There is little evidence on the effects of hGH on final height .
BACKGROUND Turner syndrome ( TS ) affects about one in 1,500 to 2,500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 - 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in women who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone on short-term growth and final height in children and adolescents with Turner syndrome .
Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome
GH is known to improve height velocity in girls with Turner syndrome ( TS ) but the optimal dosage regimen has yet to be defined
Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
Adverse effects were minimally reported .
There is little evidence of serious short-term adverse effects in these trials , but they are underpowered to detect rare adverse effects .
REVIEW ER 'S CONCLUSIONS Recombinant human growth hormone ( hGH ) doses between 0.3 - 0.375 mg/kg/wk increase short-term growth in girls with Turner Syndrome ( TS ) by approximately 3 cm in the first year of treatment and by approximately 2 cm per year after 2 years of treatment .
There is little evidence on the effects of hGH on final height .
BACKGROUND Turner syndrome ( TS ) affects about one in 1,500 to 2,500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 - 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in women who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone on short-term growth and final height in children and adolescents with Turner syndrome .